address multiple defects in type 2 diabetes with a convenient once-daily medication1,2

INVOKAMET® XR combines the mechanism of action of INVOKANA® (canagliflozin) with metformin, using a similar technology to Glumetza®1,3,4

INVOKAMET® XR & INVOKAMET® mechanism of action in kidney

Kidneys

INVOKANA® removes glucose by decreasing the renal reabsorption of filtered glucose, increasing urinary glucose excretion

INVOKAMET® XR & INVOKAMET® mechanism of action in liver

Liver

Metformin decreases hepatic glucose production

INVOKAMET® XR & INVOKAMET® mechanism of action in intestine

Intestine

Metformin decreases intestinal glucose absorption, and INVOKANA® 300 mg reduced postprandial glucose excursion due to delayed glucose absorption

  • In single-dose pharmacokinetic/pharmacodynamic studies in healthy people and in patients with type 2 diabetes

INVOKAMET® XR & INVOKAMET® mechanism of action in tissue

Peripheral tissue

Metformin improves insulin sensitivity by increasing peripheral glucose uptake and utilization

*The metformin XR layer of all INVOKAMET® XR doses contains Acuform® technology—the same XR delivery system as Glumetza® 500 mg.

Indicated trademarks are registered trademarks of their respective owners.

References: 1. INVOKAMET® XR [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 3. Depomed licenses Glumetza® data and Acuform® technology [press release]. Newark, CA: Depomed, Inc.; August 5, 2010. 4. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ.